Reuters logo
BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia
November 15, 2017 / 12:41 PM / 5 days ago

BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia

Nov 15 (Reuters) - Incyte Corp

* Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia

* Incyte Corp - ‍announced that first patient has been treated in reset pivotal trial evaluating Ruxolitinib​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below